{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["pembrolizumab","axitinib"]],"indication":"locally advanced non-metastatic clear cell renal cell carcinoma","name":"PANDORA","nct_id":"NCT04995016","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pandora-nct04995016. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PANDORA","arms":[{"description":"Neoadjuvant pembrolizumab plus axitinib","label":"Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-08-20","type":"ESTIMATED"},"conditions":["Renal Cell Carcinoma","Clear Cell Renal Cell Carcinoma"],"enrollment":{"count":18,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"},{"name":"Axitinib","otherNames":["Inlyta"],"type":"DRUG"}],"last_update":"2021-08-06","lead_sponsor":"Tianjin Medical University Second Hospital","official_title":"A Single-center, Non-randomized Controlled, Single-arm, Phase II Clinical Trial of Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2022-08-20","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Major Pathologic Response (MPR)","timeFrame":"12 weeks"}],"references":[],"start_date":{"date":"2021-08-20","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT04995016"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pandora-nct04995016"}